Analysts Set Immunocore Holdings plc (NASDAQ:IMCR) PT at $65.64

Immunocore Holdings plc (NASDAQ:IMCR) has earned a consensus rating of “Moderate Buy” from the thirteen brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $65.64.

A number of equities research analysts have commented on the company. Needham & Company LLC restated a “buy” rating and set a $71.00 price objective on shares of Immunocore in a research report on Friday, January 10th. Mizuho lowered shares of Immunocore from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $72.00 to $38.00 in a research report on Monday, November 11th. Morgan Stanley reaffirmed an “equal weight” rating and set a $35.00 price objective (down from $74.00) on shares of Immunocore in a research report on Friday, December 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research report on Monday, January 27th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new stake in Immunocore in the fourth quarter worth $25,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Immunocore by 69.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock worth $231,000 after buying an additional 3,053 shares during the last quarter. NEOS Investment Management LLC boosted its stake in shares of Immunocore by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock worth $330,000 after acquiring an additional 1,102 shares in the last quarter. Tema Etfs LLC acquired a new position in shares of Immunocore during the 4th quarter valued at about $330,000. Finally, Virtus ETF Advisers LLC increased its holdings in shares of Immunocore by 39.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company’s stock valued at $340,000 after acquiring an additional 3,238 shares during the last quarter. Institutional investors own 84.50% of the company’s stock.

Immunocore Price Performance

IMCR opened at $30.77 on Monday. Immunocore has a 12-month low of $27.69 and a 12-month high of $72.56. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The firm has a market capitalization of $1.54 billion, a P/E ratio of -32.39 and a beta of 0.77. The stock has a fifty day moving average of $30.03 and a 200-day moving average of $31.96.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.